Although SGLT2 inhibitors are not currently approved for the treatment of PCOS,and more randomized clinical trials are still needed, this family ofanti-diabetic drugs could be useful for PCOS patients due to beneficial effectson blood glucose and the cardiovascular system, which are often a problem inwomen affected by PCOS, improving comorbidities such as hypertension,dyslipidemia, diabetes mellitus, hyperuricemia, overweight, or obesity [70]. Here, SLC5A2 is linked to obesity due to melanocortin 4 receptor deficiency.